Injectable rhBMP-2-loaded chitosan hydrogel composite: osteoinduction at ectopic site and in segmental long bone defect.

Carriers for bone morphogenetic protein-2 (BMP-2) used in clinical practice still suffer from limitations such as insufficient protein retention. In addition, there is a clinical need for injectable carriers. The main objective of this study was to assess bone forming ability of rhBMP-2 combined either with chitosan hydrogel (rhBMP-2/CH) or chitosan hydrogel containing β-tricalcium phosphate (β-TCP) (rhBMP-2/CH/TCP). Formulations were first compared in a rat ectopic intramuscular bone formation model, and the optimal formulation was further evaluated in healing of 15-mm critical size defect in the radius of a rabbit. Three weeks after injection ectopically formed bone was analyzed by microcomputerized tomography (micro-CT) and histology. Significantly higher (4.7-fold) mineralized bone formation was observed in the rhBMP-2/CH/TCP group compared to rhBMP-2/CH group. In a pilot study, defect in a rabbit radius treated with rhBMP-2/CH/TCP showed incomplete regeneration at 8 weeks with composite leakage from the defect, indicating the need for formulation refinement when segmental defect repair is foreseen.

[1]  H. Seeherman,et al.  A Review of Preclinical Program Development for Evaluating Injectable Carriers for Osteogenic Factors , 2003, The Journal of bone and joint surgery. American volume.

[2]  Joseph C Wenke,et al.  The design and use of animal models for translational research in bone tissue engineering and regenerative medicine. , 2010, Tissue engineering. Part B, Reviews.

[3]  T. Einhorn.  Clinical applications of recombinant human BMPs: early experience and future development. , 2003, The Journal of bone and joint surgery. American volume.

[4]  C. Kirker-Head,et al.  Potential applications and delivery strategies for bone morphogenetic proteins. , 2000, Advanced drug delivery reviews.

[5]  R. Gurny,et al.  A novel thermoresponsive hydrogel based on chitosan. , 2008, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[6]  S. Glassman,et al.  Perioperative Complications of Recombinant Human Bone Morphogenetic Protein-2 on an Absorbable Collagen Sponge Versus Iliac Crest Bone Graft for Posterior Cervical Arthrodesis , 2009, Spine.

[7]  J. M. Badura,et al.  A comprehensive clinical review of recombinant human bone morphogenetic protein-2 (INFUSE® Bone Graft) , 2007, International Orthopaedics.

[8]  M Bohner,et al.  Calcium orthophosphates in medicine: from ceramics to calcium phosphate cements. , 2000, Injury.

[9]  H. Seeherman,et al.  Delivery of bone morphogenetic proteins for orthopedic tissue regeneration. , 2005, Cytokine & growth factor reviews.

[10]  J. Wozney,et al.  Delivering on the promise of bone morphogenetic proteins. , 2001, Trends in biotechnology.

[11]  R. Bartus,et al.  Sustained Delivery of Proteins for Novel Therapeutic Products , 1998, Science.

[12]  Robert Gurny,et al.  Physical instability, aggregation and conformational changes of recombinant human bone morphogenetic protein-2 (rhBMP-2). , 2010, International journal of pharmaceutics.

[13]  A. Reddi.  Bone Morphogenetic Proteins: From Basic Science to Clinical Applications , 2001, The Journal of bone and joint surgery. American volume.

[14]  S M Perren,et al.  Bone regeneration with resorbable polymeric membranes: treatment of diaphyseal bone defects in the rabbit radius with poly(L-lactide) membrane. A pilot study. , 1996, Journal of orthopaedic trauma.

[15]  W. Friess,et al.  Collagen sponges for bone regeneration with rhBMP-2. , 2003, Advanced drug delivery reviews.

[16]  S. Bidic,et al.  rhBMP-2 delivered in a calcium phosphate cement accelerates bridging of critical-sized defects in rabbit radii. , 2006, The Journal of bone and joint surgery. American volume.

[17]  L. Deguzman,et al.  Combination of bone marrow and TGF-beta1 augment the healing of critical-sized bone defects. , 1998, Journal of pharmaceutical sciences.

[18]  Hideki Yoshikawa,et al.  Potentiation of the activity of bone morphogenetic protein-2 in bone regeneration by a PLA-PEG/hydroxyapatite composite. , 2005, Biomaterials.

[19]  A G Mikos,et al.  In vivo release of rhBMP-2 loaded porous calcium phosphate cement pretreated with albumin , 2006, Journal of materials science. Materials in medicine.

[20]  A. Klibanov,et al.  Protein stability in controlled-release systems , 2000, Nature Biotechnology.

[21]  J. Jansen,et al.  Closing capacity of segmental radius defects in rabbits. , 2008, Journal of biomedical materials research. Part A.

[22]  S. Glassman,et al.  Adverse Effects Associated With High-Dose Recombinant Human Bone Morphogenetic Protein-2 Use in Anterior Cervical Spine Fusion , 2006, Spine.

[23]  R. Gurny,et al.  The effects of carrier nature and pH on rhBMP-2-induced ectopic bone formation. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[24]  H. Seeherman,et al.  Bone Morphogenetic Protein Delivery Systems , 2002, Spine.

[25]  A. Rodrigues,et al.  A validated 1H NMR method for the determination of the degree of deacetylation of chitosan. , 2003, Journal of pharmaceutical and biomedical analysis.

[26]  M. Casal,et al.  Bone morphogenetic proteins in tissue engineering: the road from laboratory to clinic, part II (BMP delivery) , 2008, Journal of tissue engineering and regenerative medicine.